Backed by Stanford-Start X Fund and a trio of corporates, Poynt has now received more than $128m in total for its payment processing terminal and software business.
Oxford Nanopore has secured $66m from Amgen, after the latter’s subsidiary Decode Genetics used the spinout’s technology to sequence hundreds of human genomes.
The cancer therapy developer has secured $120m in a convertible note offering featuring the University of California office of the chief investment officer.
Biontech, an immunotherapy spinout of Johannes Gutenberg University Mainz, has received an undisclosed amount of equity funding as part of a collaboration deal that could reach $425m.
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Ascentage, based on research at University of Michigan, has increased its total funding to more than $240m after closing a $150m series C round.